Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Alvotech

< Previous 1 2 3 Next >
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
From Alvotech
Via GlobeNewswire
Tickers ALVO RDY
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
From Alvotech
Via GlobeNewswire
Tickers ALVO TEVA
Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT)
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Announces Participation at BofA Securities Healthcare Conference 2024
From Alvotech
Via GlobeNewswire
Tickers ALVO
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
From Alvotech
Via GlobeNewswire
Tickers ALVO TEVA
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
From Alvotech
Via GlobeNewswire
Tickers ALVO TEVA
Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Announces Increase in Number of Own Shares
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Appoints Interim Chief Quality Officer
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
From Alvotech
Via GlobeNewswire
Tickers ALVO TEVA
Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04
From Alvotech
Via GlobeNewswire
Tickers ALVO
STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea® (aflibercept)
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech to Report Financial Results for the First Nine Months of 2023 on November 28, 2023, and Host Business Update Conference Call on November 29, 2023, at 8:00 am ET
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki™ (AVT04), the First Biosimilar of Stelara® (ustekinumab)
From Alvotech
Via GlobeNewswire
Tickers ALVO
STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelara
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech to Present at the Jefferies 2023 London Healthcare Conference
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Enters into Exclusive Licensing Agreement with Kashiv BioSciences for Development and Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Announces Approval in Japan of AVT04 (ustekinumab), a Biosimilar to Stelara®
From Alvotech
Via GlobeNewswire
Tickers ALVO
Alvotech Provides U.S. Regulatory Update on AVT02, a High-Concentration Interchangeable Biosimilar Candidate to Humira® (adalimumab)
From Alvotech
Via GlobeNewswire
Tickers ALVO
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS